Pfizer Inc. (NYSE:PFE) reported that enrollment of the first patient in a Phase 2b clinical examination of its investigational Staphylococcus aureus or S. aureus multi-antigen vaccine in adults undergoing elective spinal fusion surgery. The reason of the study, hired STRIVE, is to evaluate the safety and efficacy of the vaccine […]